Adjuvant Development Program

NIAID/DAIT佐剂开发计划支持开发新的候选疫苗佐剂，这些佐剂可以刺激先天性免疫反应，防止受到NIAID A、B和C类病原体的感染。目前，氢氧化铝/磷酸铝(明矾)是美国唯一获得许可的人类通用佐剂。由于明矾不是一种普遍有效的佐剂，人们正在寻找更多的佐剂，以激发对各种微生物更广泛、更有效和更安全的反应。有资格获得支持的候选疫苗佐剂必须：1)以前被鉴定为安全的，2)通过激活固有免疫系统发挥作用，3)具有佐剂的有据可查的作用机制，4)是产品开发计划的一部分，将在5年的合同期内显著提高产品的性能，以及5)在可能的情况下，能够在体内动物模型中针对NIAID A、B和C类病原体的致病挑战安全地增强疫苗效力。

The NIAID/DAIT Adjuvant Development Program supports the development of new candidate vaccine adjuvants that stimulate innate immune responses to protect against infection by NIAID Category A, B, and C Pathogens. Currently, aluminum hydroxide/aluminum phosphate (alum) is the only licensed adjuvant for general human use in the United States. Because alum is not a universally effective adjuvant, additional adjuvants are sought that can stimulate more broadly effective and safe responses to a wide variety of microorganisms. Candidate vaccine adjuvants eligible for support must: 1) be previously identified and characterized as safe, 2) function by activating the innate immune system, 3) have a documented mechanism of action for the adjuvant, 4) be part of a Product Development Plan that will significantly advance the product within the 5 year period of contract performance, and 5) when possible, be able to augment vaccine efficacy safely against an NIAID Category A, B, and C Pathogen upon pathogenic challenge in an in vivo animal model.